Streetbeat News

Corporate Responsibility

GOLD

Barrick Gold's CEO, Mark Bristow, argues that mergers and acquisitions won't solve the copper shortage, emphasizing the need for new copper discoveries and developments. He comments on the limitations of M&A in the context of BHP's proposed $39 billion takeover of Anglo American. Bristow highlights Barrick Gold's focus on developing its copper assets independently, particularly the Reko Diq project in Pakistan, which is expected to significantly contribute to the local economy and create thousands of jobs.

Portfolio Pulse from Stjepan Kalinic

May 09, 2024 | 1:02 pm

NSC

At the annual meeting, shareholders of Norfolk Southern Corporation voted to retain CEO Alan Shaw, demonstrating confidence in his leadership.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:59 pm

MNMD

Mind Medicine (MindMed) Inc. presented new studies at ISPOR 2024, demonstrating the significant economic and societal impact of Generalized Anxiety Disorder (GAD) in the U.S. The studies, based on data from the 2022 National Health and Wellness Survey, showed that GAD increases healthcare costs, decreases work productivity, and lowers health-related quality of life. The impact is more severe in undiagnosed cases. MindMed is developing novel treatments for GAD and other brain health disorders.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:56 pm

NSC

Preliminary voting results from the 2024 Annual Meeting indicate that Ancora has successfully secured board seats for its nominees, signaling a significant shift in leadership and strategy for the company. Shareholders showed a lack of support for current board members including Amy Miles, Jennifer Scanlon, and John Thompson, and CEO Alan Shaw received a vote of no confidence with barely 50% support. This development underscores Ancora's ongoing campaign for changes at the company, especially in light of the upcoming government report on the East Palestine derailment and toxic burn.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:55 pm

KWR

Quaker Houghton announced the appointment of Tom Coler as CFO effective June 10, 2024, succeeding Shane Hostetter. Hostetter will leave to pursue other opportunities but will remain until August 4, 2024, for a smooth transition. CEO Andy Tometich praised both Coler's financial leadership and Hostetter's contributions to the company's growth and strategic initiatives.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:54 pm

AZN

EWTX

GSK

TARS

ZLAB

As of May 9, 2024, five health care stocks are identified as overbought based on their RSI values, indicating potential short-term performance issues. Zai Lab, Tarsus Pharmaceuticals, Edgewise Therapeutics, GSK, and AstraZeneca have all shown significant gains in their stock prices recently, but their high RSI values suggest they might be at risk for a pullback. Each company has had positive developments, such as strong quarterly results or strategic board appointments, which contributed to their stock gains.

Portfolio Pulse from Avi Kapoor

May 09, 2024 | 12:44 pm

SLRN

Shao-Lee Lin, founder of ACELYRIN, has stepped down as CEO, with Mina Kim taking over the role and joining the board. SLRN, the company's stock symbol, may see market reactions.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:32 pm

ATNF

180 Life Sciences announced the resignation of James N. Woody as CEO and board member, and Dr. Jonathan Rothbard as Chief Scientific Officer, both on May 7, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:09 pm

PHAT

Phathom Pharmaceuticals announced it has enough capital to fund its operations until the end of 2026, indicating financial stability and potentially reducing immediate fundraising concerns.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:03 pm

DHR

Danaher Corporation has initiated a collaboration with Johns Hopkins University through the Danaher Beacon for Brain Injury Diagnostics project, focusing on the early and precise identification of mild Traumatic Brain Injury (TBI) using new blood-based biomarkers and Beckman Coulter Diagnostics' sensitive technology. This method may also be applicable to diagnosing other neurological conditions.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:00 pm